DEF: Microbot Medical Seeks Shareholder Approval for Key Proposals at 2025 Annual Meeting

Microbot Medical is asking shareholders to vote on several proposals at its 2025 Annual Meeting, including director elections, executive compensation, and an increase in authorized shares.

Summary

• Microbot Medical Inc. has issued a proxy statement for its 2025 Annual Meeting of Shareholders, scheduled for June 10, 2025.
• Shareholders will vote on eight proposals, including the election of three Class I directors, advisory votes on executive compensation, and approval of the issuance of Series I preferred investment options.
• A key proposal involves amending the company's Certificate of Incorporation to increase the authorized number of common stock shares.
• Another proposal seeks approval for an amendment to the 2020 Omnibus Performance Award Plan to increase the number of shares reserved for issuance by 2,591,019 shares.
• The board recommends voting FOR all director nominees and the proposals related to executive compensation, stock issuance, and the amendment to the stock award plan.
• The board recommends voting for ONE YEAR on the proposal concerning the frequency of future advisory votes on executive compensation.
• The company is also asking stockholders to ratify the selection of Brightman Almagor Zohar & Co. as the independent registered public accounting firm for the year ending December 31, 2025.

Sentiment

Score: 7

Explanation: The document is largely procedural and factual, with a positive outlook on the company's future flexibility. The board's recommendations are generally positive, but the potential for dilution and past challenges in obtaining a quorum temper the overall sentiment.

Positives

• The board is actively seeking shareholder input on executive compensation through advisory votes.
• The proposed increase in authorized shares provides the company with greater flexibility for future financing and strategic opportunities.
• The proposed amendment to the 2020 Omnibus Performance Award Plan will allow the company to continue to attract, motivate, reward and retain the talent critical to achieving our business goals.
• The company is taking steps to comply with Nasdaq listing rules and contractual obligations related to recent securities offerings.

Negatives

• Approval of the stock issuance proposal will lead to dilution of existing shareholders' ownership.
• The company previously failed to obtain a quorum for a special meeting to vote on two of the proposals, indicating potential challenges in garnering shareholder support.
• The company will incur substantial cost, and management will devote substantial time and attention, in attempting to obtain such approvals.

Risks

• Failure to approve the stock issuance proposal could impair the company's ability to raise capital and satisfy obligations related to outstanding options.
• The value of the Options will continue to be impaired if the company does not obtain approval of this Proposal at the Annual Meeting.
• The inability to exercise the Options into common stock may also materially adversely affect the Company's future ability to raise equity or debt capital from third parties on attractive terms, if at all, and also risks impairing the operations, assets and ongoing viability of the Company.

Future Outlook

The company anticipates future issuances of securities to raise capital, payment of consideration for acquisitions, and additional shares issued in connection with grants made to employees under new or expanded existing compensation plans or arrangements.

Management Comments

• By Order of the Board of Directors, Harel Gadot Chairman, President and Chief Executive Officer

Industry Context

Proxy statements are a standard part of corporate governance, providing shareholders with information needed to make informed decisions on key company matters. The proposals outlined in this proxy statement are typical for a publicly traded company seeking to maintain flexibility and align executive compensation with company performance.

Comparison to Industry Standards

• Executive compensation practices, as reflected in the say-on-pay vote, are generally compared to peer companies in the medical device or biotechnology industries.
• The proposed increase in authorized shares is a common practice among publicly traded companies to provide flexibility for future capital raising and strategic transactions.
• The structure and composition of the board committees (Audit, Compensation, and Corporate Governance) align with standard corporate governance practices for Nasdaq-listed companies.
• The company's approach to director compensation, including cash fees and equity awards, is generally consistent with industry benchmarks for companies of similar size and stage of development.

Stakeholder Impact

• Approval of the proposals will impact shareholders through potential dilution and changes in voting power.
• The outcome of the executive compensation vote will reflect shareholder sentiment on management's pay.
• Employees may be affected by changes to the stock award plan.
• The company's ability to raise capital and execute its strategic plans will be influenced by the outcome of the votes.

Next Steps

• Shareholders are encouraged to review the proxy statement and vote on the proposals.
• The company will hold its Annual Meeting of Shareholders on June 10, 2025.
• The company will file an amendment to the Certificate of Incorporation to increase the number of authorized shares to 121,000,000 and of common stock to 120,000,000, a copy of which amendment is attached hereto as Exhibit A, unless the Board of Directors determines otherwise.

Key Dates

Keywords

proxy statement, annual meeting, shareholders, directors, executive compensation, stock issuance, authorized shares, Brightman Almagor Zohar, Microbot Medical